August 16, 2025Journal of Translational MedicineOpen Access

Neoadjuvant chemoimmunotherapy versus neoadjuvant chemoradiotherapy in patients with borderline resectable esophageal squamous cell carcinoma

View Full Paper

Ask AI

Bookmark

Authors

JLJun-Peng LinFujian Medical University FZFeng-Nian ZhuangFujian Medical University WCWeijie ChenTianjin University of Traditional Chinese Medicine

Discussion

Member takes

Implication

Retrospective cohort study compares neoadjuvant chemotherapy with immunotherapy and chemoradiotherapy outcomes in patients with borderline resectable esophageal cancer, suggesting a possible safe strategy.

Key Points

Neoadjuvant chemotherapy combined with immunotherapy showed comparable outcomes to chemoradiotherapy following surgery.
Patients treated with chemoradiotherapy had a higher rate of severe postoperative complications compared to those receiving immunotherapy.
Survival rates, including overall survival and disease-free survival, were similar between the two treatment groups after surgery.
The study utilized propensity score matching to minimize confounding factors, enhancing the reliability of the findings.

Cite This Study

Lin et al. (2025) studied this question.

synapsesocial.com/papers/68af2d7ccf1dd9ea359e5931 https://doi.org/10.1186/s12967-025-06672-3

View Full Paper

Ask AI

Bookmark